Researchmoz presents this most up-to-date research on"Investigation
Report on China Imatinib Market, 2009 - 2018". The report focuses
primarily on quantitative market metrics in order to characterize the
growth and evolution of the Remote Patient Monitoring Market.
Browse Full Report With TOC At : http://www.researchmoz.us/investigation-report-on-china-imatinib-market-2009-2018-report.html
Incidence
of chronic myelogenous leukemia (CML) varies in the world. The global
incidence is about 10/1,000,000 while in China it is 4/1,000,000. CML
takes up about 20% of leukaemia in China and 95% of chronic leukemia.
CML patients vary from the very young to the very old, and the incidence
increases as people grow old.
CML treatment went through a long period of development. Interferon used to be main medication before imatinib. It was initially used in CML treatment in 1980 and became the first genetically effective drug to treat chronic phase CML-CP since 1990. About 20% to 30% patients get cytogenetic remission and live longer using interferon. However, interferon is toxic because of too many unbearable side effects.
Imatinib is originally developed by Novartis with the trade name "Gleevec". It was approved to the U.S.A. to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML) blastic phase, accelerated phase or patients in chronic phase after a-interferon failure. In November 2001 it was approved in Europe and to Chinese market in April 2002. Average survival time of CML patients used to be 3 to 6 years before imatinib was developed. Due to its revolutionary treatment, imatinib prolongs 85% to 90% CML patients' life by 10 years. With much less side effects, imatinib is significantly safer than interferon. As a result, it became a first-line drug in CML treatment soon.
CML treatment went through a long period of development. Interferon used to be main medication before imatinib. It was initially used in CML treatment in 1980 and became the first genetically effective drug to treat chronic phase CML-CP since 1990. About 20% to 30% patients get cytogenetic remission and live longer using interferon. However, interferon is toxic because of too many unbearable side effects.
Imatinib is originally developed by Novartis with the trade name "Gleevec". It was approved to the U.S.A. to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML) blastic phase, accelerated phase or patients in chronic phase after a-interferon failure. In November 2001 it was approved in Europe and to Chinese market in April 2002. Average survival time of CML patients used to be 3 to 6 years before imatinib was developed. Due to its revolutionary treatment, imatinib prolongs 85% to 90% CML patients' life by 10 years. With much less side effects, imatinib is significantly safer than interferon. As a result, it became a first-line drug in CML treatment soon.
Market Research Related Reports :
Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs
with Novel Mechanisms of Action Signal a Shift in Treatment Patterns http://www.researchmoz.us/epilepsy-therapeutics-in-major-developed-markets-to-2019-new-aeds-with-novel-mechanisms-of-action-signal-a-shift-in-treatment-patterns-report.html
Research has released its pharma research: ‘Epilepsy Therapeutics in
Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of
Action Signal a Shift in Treatment Patterns ’, which provides in-depth
analysis of epilepsy market within the eight major developed markets of
the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report
provides an estimation of the market size for 2012, along with market
forecasts to 2019. It also covers disease epidemiology, treatment
algorithms, treatment patterns, in-depth analysis of the pipeline, and
deal analysis. The value of the epilepsy market in the major developed
markets amounted to an estimated $3.4 billion in 2012 and is expected to
register a Compound Annual Growth Rate (CAGR) of 3.9% to reach $4.5
billion by 2019.
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014 http://www.researchmoz.us/competitor-analysis-biosimilar-and-biosuperior-therapeutic-antibodies-2014-report.html
The present Competitive Intelligence
Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014
provides a competitor evaluation in the field of recombinant monoclonal
and polyclonal antibodies in the market, in the pipeline as next
generation products and as biosimilar versions as of March 2014.Marketed antibodies are attractive for
companies to create next generation variants and biosimilar copies
because they represent clinically and commercially validated products.
New technologies such as Fc engineering, polyclonal mixtures, antibody
drug conjugates or bispecific molecules as well as the expiration of
patents stimulate the discovery and development of biosimilar and
biosuperior/biobetter molecules.Total sales of recombinant therapeutic
monoclonal antibodies originating from companies located in regulated
markets reached US$ 75.7 bln in the year 2013.
Browse More Related Reports At : http://www.researchmoz.us/therapeutic-area-market-reports-37.html
In 2002 imatinib gained accelerated approval from FDA to be the
first-line drug in advanced or metastatic gastrointestinal stromal
tumors (GIST) treatment. As a first-line drug in clinical treatment, the
sales revenue of imatinib exceeded USD 1 billion in 2003 and it is
still increasing rapidly.
Imatinib was approved to China in
2002 to treat CML and GIST. Its market size keeps increasing after its
launch. According to CRI's investigation on sample hospital market, the
CAGR of its sales revenue exceeded 40% from 2005 to 2012. It is
estimated that growth of original drugs will slow down because of
launched generic drugs.
The huge success of targeted antitumor drugs in the market depends greatly on high treatment cost. In China, the monthly treatment cost of imatinib is over CNY 20 thousand. Compared with traditional antitumor drugs, fewer patients are needed to make it a blockbuster drug since they need to take it for a long time.
The huge success of targeted antitumor drugs in the market depends greatly on high treatment cost. In China, the monthly treatment cost of imatinib is over CNY 20 thousand. Compared with traditional antitumor drugs, fewer patients are needed to make it a blockbuster drug since they need to take it for a long time.
For Market Research Latest Reports Visit At : http://www.researchmoz.us/latest-report.html
Through this report, the readers can acquire the following information:
Market Share of Major Imatinib Manufacturers in Sample Hospitals in China
Sales price of Imatinib in Hospital Market in China
Share of Imatinib in Different Dosage Forms in China Hospital Market
Incidence of CML in China
Manufacturing Schedule of Imatinib Generic Drug
Prospect of China Imatinib Market
Market Share of Major Imatinib Manufacturers in Sample Hospitals in China
Sales price of Imatinib in Hospital Market in China
Share of Imatinib in Different Dosage Forms in China Hospital Market
Incidence of CML in China
Manufacturing Schedule of Imatinib Generic Drug
Prospect of China Imatinib Market
For More Information Kindly Contact:
Email: sales@researchmoz.us
Web Site: http://www.researchmoz.us/
Blog: http://deepmarketresearchreports.blogspot.com/
word press : http://marketresearchtopix.wordpress.com
Email: sales@researchmoz.us
Web Site: http://www.researchmoz.us/
Blog: http://deepmarketresearchreports.blogspot.com/
word press : http://marketresearchtopix.wordpress.com
0 comments:
Post a Comment